aibioTaysha Gene Therapies holders approve raising authorized shares to 700,000,000
Tickers TSHA
Common stock authorized rises from 400,000,000 shares. The company filed the amendment in Delaware on June 2, 2025.
Key facts
- Company
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
- News type
- Listings
- Primary source
- Taysha Gene Therapies, Inc. 8-K (2025-06-03)
Taysha Gene Therapies, Inc. (TSHA) stockholders approved an amendment to the company's Amended and Restated Certificate of Incorporation that increases authorized common stock from 400,000,000 shares to 700,000,000 shares. The vote took place at the 2025 annual meeting on June 2, 2025. The company filed the amendment with the Secretary of State of the State of Delaware the same day.
Authorized shares are the maximum a company can issue. The proposal received 171,348,017 votes for, 8,177,868 against and 89,390 abstentions. Of the 205,054,570 shares outstanding as of the record date, 179,615,275 shares, or approximately 87%, were present or represented by proxy.
Stockholders also elected Phillip B. Donenberg, CPA, and Sukumar Nagendran, M.D., as directors to serve until the 2028 annual meeting of stockholders. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 179,419,717 votes for.